里昂发表研究报告，对中资医药股最新评级及目标价如下： 股份│投资评级│目标价(港元) 相关内容《大行》麦格理对中国CDMO及生物科技股投资评级及目标价(表)中生制药(01177.HK) +0.150 (+2.060%) 沽空 $8.91千万; 比率 17.978% │买入│14.17元石药(01093.HK) +0.260 (+2.968%) 沽空 $1.33亿; 比率 16.850% │买入│23.37元三生制药(01530.HK) -0.180 (-0.636%) 沽空 $7.91千万; 比率 12.853% │买入│17.43元复星医药(02196.HK) +0.460 (+1.936%) 沽空 $7.43百万; 比率 12.233% │跑输大市│23.53元翰森制药(03692.HK) -0.080 (-0.219%) 沽空 $3.52千万; 比率 19.940% │跑赢大市│30.77元中国同辐(01763.HK) +1.500 (+9.482%) │买入│26.78元百济神州(06160.HK) +5.200 (+2.842%) 沽空 $7.99千万; 比率 14.524% │买入│144.04元华领医药(02552.HK) +0.090 (+2.493%) 沽空 $27.03万; 比率 2.706% │买入│10.34元药明生物(02269.HK) +0.800 (+2.275%) 沽空 $8.80千万; 比率 14.301% │买入│102.62->139.69元药明康德(02359.HK) +2.500 (+2.458%) 沽空 $7.15千万; 比率 20.607% │买入│115.63->142.37元方达控股(01521.HK) +0.010 (+0.909%) │跑赢大市->买入│5.97元康龙化成(03759.HK) +0.820 (+3.516%) 沽空 $1.15千万; 比率 13.174% │买入│53.69->68.25元国药(01099.HK) +0.290 (+1.574%) 沽空 $1.80千万; 比率 19.955% │买入│38.69元华润医药(03320.HK) +0.010 (+0.211%) 沽空 $1.98千万; 比率 54.695% │买入│14.21元上海医药(02607.HK) +0.170 (+1.421%) 沽空 $22.23万; 比率 1.054% │买入│24.04元锦欣生殖(01951.HK) +0.040 (+1.613%) 沽空 $2.95百万; 比率 7.229% │跑赢大市->买入│15.37元 (sw/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-10-20 16:25。)